Status:
COMPLETED
Retrospective Study in Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR)
Lead Sponsor:
Groupe Francais De Pneumo-Cancerologie
Conditions:
NSCLC Non Small Cells Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of our retrospective study is to describe which circumstances EGFR TKI is continued despite progression according to the usual Response Evaluation CrIteria in Solid Tumours (RECIST) in pat...
Detailed Description
Background : • Lung cancer represents the leading cause of death by cancer in France. Significant advances have been made in recent years on knowledge of oncogenesis of NSCLC in particularly the disc...
Eligibility Criteria
Inclusion
- Eligibility criteria:
- Inclusion criteria:
- NSCLC patients with activating mutations of EGFR
- First-line treatment with a TKI monotherapy
- Measurable lesion according to RECIST 1.1
- Age\> 18 years
- secondary or acquired resistance of EGFR TKIs according to the jackman criteria
- patients for whom it was started a TKI treatment in first line from January 2010 until June 2012 (patients who received 1 Chemotherapy cycle could be included).
- Exclusion criteria:
- Patients with small cell carcinoma
- Patients without EGFR mutation
- Patients not treated with EGFR TKI in first line treatment
- Not measurable lesion to RECIST 1.1
Exclusion
Key Trial Info
Start Date :
January 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2014
Estimated Enrollment :
144 Patients enrolled
Trial Details
Trial ID
NCT02293733
Start Date
January 1 2014
End Date
March 1 2014
Last Update
November 18 2014
Active Locations (24)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier D Argenteuil
Argenteuil, Val D'oise, France, 95100
2
Site 12
Aix-en-Provence, France, 13100
3
Centre Hospitalier Universitaire
Angers, France, 49033
4
Centre Hospitalier du Morvan
Brest, France, 29200